HUP0204513A3 - Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients - Google Patents
Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredientsInfo
- Publication number
- HUP0204513A3 HUP0204513A3 HU0204513A HUP0204513A HUP0204513A3 HU P0204513 A3 HUP0204513 A3 HU P0204513A3 HU 0204513 A HU0204513 A HU 0204513A HU P0204513 A HUP0204513 A HU P0204513A HU P0204513 A3 HUP0204513 A3 HU P0204513A3
- Authority
- HU
- Hungary
- Prior art keywords
- release
- controlling
- fatty acid
- acid esters
- active ingredients
- Prior art date
Links
- 229930006000 Sucrose Natural products 0.000 title 1
- 239000004480 active ingredient Substances 0.000 title 1
- 235000014113 dietary fatty acids Nutrition 0.000 title 1
- 235000013681 dietary sucrose Nutrition 0.000 title 1
- 229930195729 fatty acid Natural products 0.000 title 1
- 239000000194 fatty acid Substances 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- -1 saccharose fatty acid esters Chemical class 0.000 title 1
- 229960004793 sucrose Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2000110509 DE10010509A1 (de) | 2000-03-08 | 2000-03-08 | Pharmazeutische Formulierungen |
US18796200P | 2000-03-09 | 2000-03-09 | |
PCT/EP2001/002500 WO2001066081A2 (de) | 2000-03-08 | 2001-03-06 | Pharmazeutische formulierungen enthaltend saccharosefettsäureester zur steuerung der wirkstofffreisetzung |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0204513A2 HUP0204513A2 (en) | 2003-05-28 |
HUP0204513A3 true HUP0204513A3 (en) | 2004-06-28 |
Family
ID=26004678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0204513A HUP0204513A3 (en) | 2000-03-08 | 2001-03-06 | Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP1267828B1 (hu) |
JP (1) | JP2003528829A (hu) |
KR (1) | KR20020083171A (hu) |
CN (1) | CN1212831C (hu) |
AT (1) | ATE334659T1 (hu) |
AU (1) | AU2001250365A1 (hu) |
BG (1) | BG107064A (hu) |
BR (1) | BR0109036A (hu) |
CA (1) | CA2339913C (hu) |
CZ (1) | CZ20023009A3 (hu) |
DE (1) | DE50110617D1 (hu) |
EA (1) | EA200200951A1 (hu) |
EE (1) | EE200200504A (hu) |
GE (1) | GEP20053455B (hu) |
HK (1) | HK1054697A1 (hu) |
HR (1) | HRP20020804B1 (hu) |
HU (1) | HUP0204513A3 (hu) |
IS (1) | IS6511A (hu) |
NO (1) | NO20024237L (hu) |
NZ (1) | NZ521215A (hu) |
PL (1) | PL202935B1 (hu) |
SK (1) | SK13252002A3 (hu) |
WO (1) | WO2001066081A2 (hu) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1490031A1 (en) * | 2002-03-07 | 2004-12-29 | Vectura Limited | Fast melt multiparticulate formulations for oral delivery |
CA2509259A1 (en) * | 2003-01-23 | 2004-08-05 | Amorepacific Corporation | Sustained-release preparations and method for producing the same |
DE10341264A1 (de) * | 2003-09-04 | 2005-03-24 | Grünenthal GmbH | Schmelzformulierte, multipartikuläre orale Darreichungsform |
JP2007533733A (ja) * | 2004-04-22 | 2007-11-22 | モル リサーチ アプリケーションズ リミテッド | 食物摂取管理の方法 |
AU2009270768A1 (en) * | 2008-07-18 | 2010-01-21 | Valeant Pharmaceuticals International | Modified release formulation and methods of use |
US8715715B2 (en) * | 2008-11-03 | 2014-05-06 | Nal Pharmaceuticals Ltd. | Dosage form for insertion into the mouth |
DE102009013613A1 (de) | 2009-03-17 | 2010-09-23 | Ratiopharm Gmbh | Trockenverarbeitung von Retigabin |
DE102009013612A1 (de) | 2009-03-17 | 2010-09-23 | Ratiopharm Gmbh | Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung |
DE102009013611A1 (de) | 2009-03-17 | 2010-09-23 | Ratiopharm Gmbh | Festes Retigabin in nicht-kristalliner Form |
BR112012018173A2 (pt) * | 2010-01-20 | 2017-08-29 | Valeant Pharmaceuticals Int | "formulação de liberação modificada e método de uso" |
EP2729176A1 (en) | 2011-07-05 | 2014-05-14 | Contera Pharma APS | The use of serotonin receptor agonists for treatment of movement disorders |
US9616025B2 (en) * | 2013-10-29 | 2017-04-11 | Echo Pharmaceuticals B.V. | Compressed tablet containing Δ9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment |
US11331268B2 (en) * | 2016-11-18 | 2022-05-17 | The University Of Western Australia | Taste masking product |
CN107441055A (zh) * | 2017-08-03 | 2017-12-08 | 山东则正医药技术有限公司 | 一种控释药物的制备方法 |
CN108853044B (zh) * | 2018-07-06 | 2020-11-06 | 郑州明泽医药科技有限公司 | 一种硝苯地平缓释片及其制备方法 |
CN109679147B (zh) * | 2018-12-28 | 2021-05-11 | 广西科技师范学院 | 植物微细纤维蔗糖脂肪酸酯富集物及制备方法 |
GB201904767D0 (en) | 2019-04-04 | 2019-05-22 | Orexo Ab | New pharmaceutical compositions |
WO2021145625A1 (ko) * | 2020-01-13 | 2021-07-22 | 한국유나이티드제약 주식회사 | R-치옥트산 또는 이의 약학적으로 허용되는 염 및 장용코팅기제를 포함하는 약학조성물 |
CN111513192A (zh) * | 2020-05-19 | 2020-08-11 | 北京中联华康科技有限公司 | 一种酯化半胱胺盐酸盐稳定型粉末及其制备方法与应用 |
CN114983964B (zh) * | 2022-06-24 | 2024-05-03 | 广东恒健制药有限公司 | 一种头孢地尼颗粒剂及其制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63101320A (ja) * | 1986-10-17 | 1988-05-06 | Dainippon Pharmaceut Co Ltd | バルプロ酸カルシウム製剤 |
JPH07267850A (ja) * | 1994-03-28 | 1995-10-17 | Eisai Co Ltd | 不快味を防止した医薬組成物及びその製造方法 |
JP4078567B2 (ja) * | 1997-04-25 | 2008-04-23 | 東和薬品株式会社 | 徐放性マイクロカプセル及びその製法 |
JP4299384B2 (ja) * | 1997-07-15 | 2009-07-22 | 富山化学工業株式会社 | 溶出遅延防止細粒剤 |
HU230889B1 (hu) * | 1998-03-26 | 2018-12-28 | Astellas Pharma Inc. | Késleltetett felszabadulású gyógyszerkészítmények |
DE19840152A1 (de) * | 1998-09-03 | 2000-03-09 | Dresden Arzneimittel | Calciumvalproat enthaltende pharmazeutische Zusammensetzungen mit retardierter Wirkstoff-Freisetzung, Verfahren zu deren Herstellung und deren Verwendung |
DE19916383A1 (de) * | 1999-03-31 | 2000-10-05 | Schering Ag | Pharmazeutische Zusammensetzung mit einem Extrusionsstoff |
-
2001
- 2001-03-06 CN CNB018061893A patent/CN1212831C/zh not_active Expired - Fee Related
- 2001-03-06 NZ NZ521215A patent/NZ521215A/en unknown
- 2001-03-06 DE DE50110617T patent/DE50110617D1/de not_active Revoked
- 2001-03-06 PL PL362547A patent/PL202935B1/pl not_active IP Right Cessation
- 2001-03-06 JP JP2001564734A patent/JP2003528829A/ja active Pending
- 2001-03-06 EA EA200200951A patent/EA200200951A1/ru unknown
- 2001-03-06 BR BR0109036-4A patent/BR0109036A/pt not_active Application Discontinuation
- 2001-03-06 HU HU0204513A patent/HUP0204513A3/hu unknown
- 2001-03-06 CZ CZ20023009A patent/CZ20023009A3/cs unknown
- 2001-03-06 EE EEP200200504A patent/EE200200504A/xx unknown
- 2001-03-06 AT AT01923641T patent/ATE334659T1/de not_active IP Right Cessation
- 2001-03-06 SK SK1325-2002A patent/SK13252002A3/sk not_active Application Discontinuation
- 2001-03-06 WO PCT/EP2001/002500 patent/WO2001066081A2/de active IP Right Grant
- 2001-03-06 AU AU2001250365A patent/AU2001250365A1/en not_active Abandoned
- 2001-03-06 KR KR1020027011672A patent/KR20020083171A/ko not_active Application Discontinuation
- 2001-03-06 EP EP01923641A patent/EP1267828B1/de not_active Revoked
- 2001-03-06 GE GE4946A patent/GEP20053455B/en unknown
- 2001-03-07 CA CA002339913A patent/CA2339913C/en not_active Expired - Fee Related
-
2002
- 2002-08-20 IS IS6511A patent/IS6511A/is unknown
- 2002-09-05 BG BG107064A patent/BG107064A/bg unknown
- 2002-09-05 NO NO20024237A patent/NO20024237L/no not_active Application Discontinuation
- 2002-10-07 HR HR20020804A patent/HRP20020804B1/xx not_active IP Right Cessation
-
2003
- 2003-09-30 HK HK03107084A patent/HK1054697A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2001066081A2 (de) | 2001-09-13 |
WO2001066081A3 (de) | 2002-03-14 |
NO20024237D0 (no) | 2002-09-05 |
PL362547A1 (en) | 2004-11-02 |
AU2001250365A1 (en) | 2001-09-17 |
HRP20020804B1 (en) | 2008-06-30 |
HRP20020804A2 (en) | 2004-12-31 |
HUP0204513A2 (en) | 2003-05-28 |
HK1054697A1 (en) | 2003-12-12 |
EP1267828B1 (de) | 2006-08-02 |
NZ521215A (en) | 2005-04-29 |
SK13252002A3 (sk) | 2003-07-01 |
EE200200504A (et) | 2004-02-16 |
NO20024237L (no) | 2002-09-05 |
PL202935B1 (pl) | 2009-08-31 |
EP1267828A2 (de) | 2003-01-02 |
EA200200951A1 (ru) | 2003-02-27 |
GEP20053455B (en) | 2005-02-25 |
CZ20023009A3 (cs) | 2003-06-18 |
CN1418091A (zh) | 2003-05-14 |
CN1212831C (zh) | 2005-08-03 |
IS6511A (is) | 2002-08-20 |
KR20020083171A (ko) | 2002-11-01 |
BR0109036A (pt) | 2003-03-18 |
ATE334659T1 (de) | 2006-08-15 |
BG107064A (bg) | 2003-04-30 |
JP2003528829A (ja) | 2003-09-30 |
CA2339913C (en) | 2009-02-24 |
CA2339913A1 (en) | 2001-09-08 |
DE50110617D1 (de) | 2006-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0204513A3 (en) | Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients | |
HUP0303881A3 (en) | Pharmaceutical compositions containing fatty alcohols and fatty acid esters useful for treatment of inflammation | |
AU2093101A (en) | Compositions for efficient release of active ingredients | |
HUP0004133A3 (en) | Combined use of progestin and polycarboxilic acid for the preparation of pharmaceutical compositions for controlled bleeding | |
AU1928501A (en) | Formulations for pharmaceutical agents ionizable as free acids or free bases | |
HUT57541A (en) | Fungicidal compositions comprising substituted acrylic acid esters as active ingredient and process for producing the active ingredients | |
EP1369422A4 (en) | METHOD FOR PRODUCING ALKENYLPHOSPHINOXIDES OR ALKENYLPHOSPHINIC ACID ESTERS | |
ZA988718B (en) | Drug formulation having controlled release of active compound | |
AU5025300A (en) | Compositions for controlled release of the hormone gnrh and its analogs | |
HUP0102401A3 (en) | Novel intermediates and processes for the preparation of optically active octanoic acid derivatives | |
AU2001227030A1 (en) | Pharmaceutical composition for controlled release of an active ingredient | |
AU6386801A (en) | System for the release of active ingredients | |
HUP0203787A3 (en) | Benzoic acid esters of oxazolidinones having a hydroxyacetylpiperazine substituent, pharmaceutical compositions containing them and their use | |
AU2002243643A1 (en) | Estradiol-16alpha-carboxylic acid esters as locally active estrogens | |
AU2001221695A1 (en) | Solid pharmaceutical compositions for controlled release of active substances | |
AU2002323075A1 (en) | New methods for the preparation of propylene glycol fatty acid esters | |
AU2001242376A1 (en) | Process for the preparation of 2-hydroxy-4-methylthiobutyric acid esters | |
AU4340796A (en) | Use of lauric acid esters as potency increasing agents for active substances | |
BG106952A (en) | Controlled release pharmaceutical composition containing tramadol hydrochloride and method for its preparation | |
AU6557800A (en) | Process for the preparation of substituted 3-phenyl-propanoic acid esters and substituted 3-phenyl-propanoic acids | |
AU6557700A (en) | Process for the preparation of substituted 3-phenyl-propanoic acid esters and substituted 3-phenyl-propanoic acids | |
IL122919A (en) | Preparation of 1-alkyl-pyrazole-5- carboxylic acid esters | |
AU4886201A (en) | Use of vitamin b1 as agents for controlling plant diseases | |
IL161768A0 (en) | Carboxylic acid derivative compounds and drugs containing the same as the active ingredient | |
AU2002212200A1 (en) | Controlled release pharmaceutical pellet compositions for reducing side effects of drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |